CANCER TREATMENT CENTERS OF AMERICA and the National Football League Alumni Association announced a new partnership to raise awareness among NFL alumni and fans about screening, diagnosis and treatment for prostate cancer. The partnership also calls for CTCA to treat NFL alumni who are fighting the disease.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
